Yunjie Fu

39PUBLICATIONS
127CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyInnate immunityEpigenetics (incl. genome methylation and epigenomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Nov 05, 2026
Antibody-drug conjugates: unpacking toxicity profiles and optimized designs for enhanced safety and antitumor efficacy.

|Aug 26, 2026
AdvanTIG-301: a phase III study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer.

|Aug 06, 2026
Comparative safety profiles of antibody-drug conjugates: a real-world analysis of monotherapy and combination regimens in solid tumors.

|Jul 28, 2026
Ceralasertib Plus Durvalumab in Chinese Patients with Advanced Solid Tumors: A Nonrandomized Clinical Trial.

|Mar 12, 2026
Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.

Jian-Chun Duan, Jia Zhong, Bo-Yang Sun

|Oct 24, 2025
Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies.

Yan Sun, Haochen Yang, Qing Xu

Pageof 7

Frequent Collaborators

6 joint publications

Jianchun Duan

6 joint publications

Jiachen Xu

5 joint publications

Zhijie Wang

4 joint publications

Jianchun Duan